George Cardoza Sells 2,413 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CFO George Cardoza sold 2,413 shares of SOPHiA GENETICS stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $4.88, for a total transaction of $11,775.44. Following the completion of the transaction, the chief financial officer owned 292,861 shares in the company, valued at approximately $1,429,161.68. This trade represents a 0.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

• On Monday, April 6th, George Cardoza sold 2,520 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $12,222.00.
• On Thursday, March 19th, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $3,707.46.

SOPHiA GENETICS Trading Down 0.3%

Shares of SOPH traded down $0.01 during mid-day trading on Wednesday, reaching $4.89. The company had a trading volume of 64,929 shares, compared to its average volume of 188,371. The stock has a market cap of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The firm has a fifty day simple moving average of $4.78 and a 200-day simple moving average of $4.68. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $5.70. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. On average, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of hedge funds have recently made changes to their positions in SOPH. Savvy Advisors Inc. purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $48,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $49,000. Perkins Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $49,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of research reports. Guggenheim raised their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.